Newly diagnosed PAH patients on triple therapy have fewer hospitalizations vs. double therapy

PHA Canada
Feb 18
1 min read

A study looked at about 3000 pulmonary arterial hypertension patients and found that people who added selexipag to double therapy (an endothelin receptor agonist like ambrisentan, macitentan, or bosentan and a phosphodiesterase type 5 inhibitor like sildenafil or tadalafil) within six months had a lower risk of hospitalization and disease progression. They suggest that delaying the start of triple therapy contributes to worse outcomes.

Read the JAMA Network Open paper

Recent Posts

Racial and ethnic equity in PAH clinical trials

Looking at the racial and ethnic breakdown of patients with PAH and patients who take part in clinical trials, the authors conclude that the goal of equitable representation has not yet been reached.

Air pollution may worsen PAH

Air pollution is known to be bad for heart and lung diseases, but this study looked at whether it affected pulmonary arterial hypertension (PAH) in particular. They followed a cohort of patients for a

Kettlebell exercise training was safe and effective for PAH patients

A small study of patients with stable pulmonary arterial hypertension (PAH) were randomly assigned to either no exercise program or an exercise program using kettlebells three days per week for 8 week

Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.